Usca Ria LLC grew its holdings in GlaxoSmithKline plc (NYSE:GSK) by 19.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,537 shares of the pharmaceutical company’s stock after acquiring an additional 11,372 shares during the period. Usca Ria LLC’s holdings in GlaxoSmithKline were worth $2,695,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in GSK. Dubuque Bank & Trust Co. lifted its position in shares of GlaxoSmithKline by 195.3% in the fourth quarter. Dubuque Bank & Trust Co. now owns 685 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 453 shares in the last quarter. Lavaca Capital LLC purchased a new stake in shares of GlaxoSmithKline in the fourth quarter worth about $37,000. Contravisory Investment Management Inc. purchased a new stake in shares of GlaxoSmithKline in the fourth quarter worth about $49,000. River Wealth Advisors LLC lifted its position in shares of GlaxoSmithKline by 17.8% in the fourth quarter. River Wealth Advisors LLC now owns 1,990 shares of the pharmaceutical company’s stock worth $76,000 after buying an additional 301 shares in the last quarter. Finally, Clean Yield Group purchased a new stake in shares of GlaxoSmithKline in the fourth quarter worth about $90,000. Institutional investors and hedge funds own 10.99% of the company’s stock.
GSK has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of GlaxoSmithKline in a research report on Tuesday, December 11th. Morgan Stanley initiated coverage on GlaxoSmithKline in a research report on Friday, December 14th. They issued an “underweight” rating on the stock. Exane BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, December 3rd. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $41.99.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a return on equity of 160.39% and a net margin of 11.45%. The company had revenue of $10.55 billion for the quarter, compared to analysts’ expectations of $9.85 billion. As a group, equities research analysts anticipate that GlaxoSmithKline plc will post 2.89 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 22nd will be paid a dividend of $0.597 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.39 annualized dividend and a yield of 5.94%. The ex-dividend date is Thursday, February 21st. GlaxoSmithKline’s payout ratio is presently 74.68%.
TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Shares Bought by Usca Ria LLC” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4196137/glaxosmithkline-plc-gsk-shares-bought-by-usca-ria-llc.html.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: What are catch-up contributions?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.